As the active substances included in this Regulation do not fall in the prioritised categories of Implementing Decision C(2016)6104, their approval period should be extended by either two or three years, taking into account the current date of expiry, the fact that in accordance with Article 6(3) of Implementing Regulation (EU) No 844/2012 the supplementary dossier for an active substance is to be submitted no later than 30 months before expiry of the approval, the need to ensure a balanced distribution of responsibilities and work among Member States acting as rapporteurs and co-rapporteurs and the available resources necessary for assessment and decision-making. It is therefore appropriate to extend the approval period for the active substance buprofezin by two years, and to extend the approval periods of the active substances bromuconazole, haloxyfop-P and napropamide by three years.
Recital 6, Regulation (EU) 2018/670
In forcesince 30 Apr 2018
- celex=32012R0844